L'édition de cet ISBN n'est malheureusement plus disponible.
Afficher les exemplaires de cette édition ISBNLes informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Frais de port :
Gratuit
Vers Etats-Unis
Description du livre Hardcover. Etat : new. N° de réf. du vendeur 9783642209093
Description du livre Etat : New. N° de réf. du vendeur ABLIING23Mar3113020220685
Description du livre Etat : New. N° de réf. du vendeur 12655917-n
Description du livre Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Presents the recent advances in antibody engineering and in the various clinical applicationsAn invaluable resource for both experts and those new to the fieldWith contributions by international experts from research and biotech companies. N° de réf. du vendeur 5052371
Description du livre Etat : New. PRINT ON DEMAND Book; New; Fast Shipping from the UK. No. book. N° de réf. du vendeur ria9783642209093_lsuk
Description du livre Buch. Etat : Neu. Neuware -The concept of using bispecific antibodies for cancer therapy by retargeting immune effector cells was developed several years ago. Initial clinical studies were rather disappointing mainly due to low efficacy, severe side effects and the immunogenicity of the bispecific antibodies. The progress in antibody engineering finally led to the generation of new classes of bispecific antibodies lacking these obstacles. In addition, new applications were established, such as pre-targeting strategies in radioimmunotherapy and dual targeting approaches in order to improve binding, selectivity and efficacy.In this book, the different ways of generating bispecific antibodies are described, with emphasis on recombinant formats. The various applications of bispecific antibodies, e.g. in cellular cancer immunotherapy, radioimmunotherapy and pretargeting strategies are covered, and emerging applications such as dual targeting strategies, which involve the simultaneous inhibition of two targets, are addressed. 392 pp. Englisch. N° de réf. du vendeur 9783642209093
Description du livre Etat : New. N° de réf. du vendeur 12655917-n
Description du livre Buch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - The concept of using bispecific antibodies for cancer therapy by retargeting immune effector cells was developed several years ago. Initial clinical studies were rather disappointing mainly due to low efficacy, severe side effects and the immunogenicity of the bispecific antibodies. The progress in antibody engineering finally led to the generation of new classes of bispecific antibodies lacking these obstacles. In addition, new applications were established, such as pre-targeting strategies in radioimmunotherapy and dual targeting approaches in order to improve binding, selectivity and efficacy.In this book, the different ways of generating bispecific antibodies are described, with emphasis on recombinant formats. The various applications of bispecific antibodies, e.g. in cellular cancer immunotherapy, radioimmunotherapy and pretargeting strategies are covered, and emerging applications such as dual targeting strategies, which involve the simultaneous inhibition of two targets, are addressed. N° de réf. du vendeur 9783642209093
Description du livre Hardcover. Etat : Brand New. 1st edition. 373 pages. 9.00x6.25x1.00 inches. In Stock. N° de réf. du vendeur x-3642209092
Description du livre Etat : New. This book explores processes for generating bispecific antibodies, their applications in cellular cancer immunotherapy, radioimmunotherapy and pretargeting strategies, and emerging applications such as the simultaneous inhibition of two targets. Editor(s): Kontermann, Roland. Num Pages: 373 pages, biography. BIC Classification: MJCL; MJCM. Category: (P) Professional & Vocational. Dimension: 242 x 164 x 26. Weight in Grams: 704. . 2011. 2011th Edition. Hardcover. . . . . N° de réf. du vendeur V9783642209093